XML 83 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Liability Related to the Sale of Future Royalties - Narrative (Details) - Royalty Pharma Agreement - USD ($)
$ in Millions
 1 Months Ended
Nov. 30, 2022
Mar. 31, 2024
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Upfront payment $ 250.0  
Milestone payment receivable 160.0  
Milestone payment receivable upon FDA approval 50.0  
Milestone payment receivable upon receipt of royalty payments 60.0  
Royalty payment threshold 70.0  
Liability related to the sale of future royalties   $ 250.0
Liability related to the sale of future royalties, interest rate   9.30%
Amgen    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial   $ 50.0
Maximum    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]    
Initial transaction price $ 410.0